Active agents and methods of their use for the treatment of metabolic disorders and nonalcoholic fatty liver disease
Steven John Taylor, Winchester, MA (US); John Robert Proudfoot, Newtown, CT (US); Mi-Jeong Kim, Boston, MA (US); Kathleen Nudel, Jamaica Plain, MA (US); Timothy F. Briggs, Waltham, MA (US); Afrand Kamali Sarvestani, Somerville, MA (US); Leonard Buckbinder, East Greenwich, RI (US); Bernard Lanter, Somerville, MA (US); Ferdinand Edward Massari, Beverly, MA (US); Koji Yasuda, Boston, MA (US); Spencer Cory Peck, Watertown, MA (US); Cheri Snedeker, Boston, MA (US); Diana Le, Reading, MA (US); Jessica Alexander, Waltham, MA (US); Anna Liang, Everett, MA (US); Dinara Gunasekera, Cambridge, MA (US); David Arthur Berry, Waban, MA (US); and John Patrick Casey, Jr., Boston, MA (US)
Assigned to Flagship Pioneering Innovations V, Inc., Cambridge, MA (US)
Filed by Flagship Pioneering Innovations V, Inc., Cambridge, MA (US)
Filed on Nov. 17, 2020, as Appl. No. 16/950,120.
Application 16/950,120 is a continuation of application No. 16/803,411, filed on Feb. 27, 2020, granted, now 10,953,027.
Application 16/803,411 is a continuation of application No. PCT/US2019/035680, filed on Jun. 5, 2019.
Claims priority of provisional application 62/828,958, filed on Apr. 3, 2019.
Claims priority of provisional application 62/776,448, filed on Dec. 6, 2018.
Claims priority of provisional application 62/776,455, filed on Dec. 6, 2018.
Claims priority of provisional application 62/680,977, filed on Jun. 5, 2018.
Claims priority of provisional application 62/680,976, filed on Jun. 5, 2018.
Prior Publication US 2021/0177877 A1, Jun. 17, 2021
1. A method of modulating a metabolic marker or a nonalcoholic fatty liver disease marker in a subject in need thereof or of ameliorating a metabolic disorder or nonalcoholic fatty liver disease in a subject in need thereof, the method comprising administering to the subject an effective amount of an active agent selected from the following structure:
